EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?

References

• ZhouCWuYLChenGFinal overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)Ann Oncol20152691877188326141208
   PubMed Web of Science ®Google Scholar
• SchuetteWSchirmacherPEberhardtWEEGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational studyCancer Epidemiol Biomarkers Prev20152481254126126070531
   PubMed Web of Science ®Google Scholar
• VenugopalanALeeMJNiuGEGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse modelsOncotarget2016734541375415627494838
   PubMedGoogle Scholar
• LiNYangLOuWZhangLZhangSLWangSYMeta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancerPLoS One201497e10277725029199
   PubMed Web of Science ®Google Scholar
• WangSCangSLiuDThird-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancerJ Hematol Oncol201693427071706
   PubMed Web of Science ®Google Scholar
• WangSTsuiSTLiuCSongYLiuDEGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancerJ Hematol Oncol2016915927448564
   PubMed Web of Science ®Google Scholar
• KeedyVLTeminSSomerfieldMRAmerican Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapyJ Clin Oncol201129152121212721482992
   PubMed Web of Science ®Google Scholar
• FelipEGridelliCBaasPRosellRStahelRPanel MembersMetastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO consensus conference in lung cancer; Lugano 2010Ann Oncol20112271507151921536661
   PubMed Web of Science ®Google Scholar
• LindemanNICaglePTBeasleyMBMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular PathologyArch Pathol Lab Med2013137682886023551194
   PubMed Web of Science ®Google Scholar
• ChoSHParkLCJiJHEfficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutationCancer Chemother Pharmacol201270231532022760226
   PubMedGoogle Scholar
• MiyamaeYShimizuKHiratoJSignificance of epidermal growth factor receptor gene mutations in squamous cell lung carcinomaOncol Rep201125492192821318227
   PubMedGoogle Scholar
• FangWZhangJLiangWEfficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutationJ Thorac Dis20135558559224255770
   PubMedGoogle Scholar
• XuJZhangYJinBEfficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in ChinaJ Cancer Res Clin Oncol201614261325133026942444
   PubMed Web of Science ®Google Scholar
• WuYLZhongWZLiLYEpidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland ChinaJ Thorac Oncol20072543043917473659
   PubMed Web of Science ®Google Scholar
• ShiYAuJSThongprasertSA prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small cell lung cancer of adenocarcinoma histology (PIONEER)J Thorac Oncol20149215416224419411
   PubMed Web of Science ®Google Scholar
• HosokawaSToyookaSFujiwaraYComprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancerLung Cancer200966110711319185949
   PubMed Web of Science ®Google Scholar
• MidhaADeardenSMcCormackREGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)Am J Cancer Res2015592892291126609494
   PubMed Web of Science ®Google Scholar
• ChouguleAPrabhashKNoronhaVFrequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicityPLoS One2013810e7616424124538
   PubMed Web of Science ®Google Scholar
• ShukuyaTTakahashiTKairaREfficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reportsCancer Sci201110251032103721272159
   PubMedGoogle Scholar
• NoronhaVPrabhashKThavamaniAEGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapyPLoS One201384e6156123620765
   PubMedGoogle Scholar
• MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
   PubMed Web of Science ®Google Scholar
• RosellRCarcerenyEGervaisRSpanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana OncologiaToracicaErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar
• KawanoOSasakiHEndoKPIK3CA mutation status in Japanese lung cancer patientsLung Cancer200654220921516930767
   PubMed Web of Science ®Google Scholar
• HammermanPSJannePAJohnsonBEResistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerClin Cancer Res2009157502750920008850
   PubMed Web of Science ®Google Scholar
• LeeSYJinGChoiJESomatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancersJ Thorac Oncol20105111734174020881644
   PubMed Web of Science ®Google Scholar
• MaWGilliganBMYuanJLiTCurrent status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyJ Hematol Oncol2016914727234522
   PubMed Web of Science ®Google Scholar
• ZhouQYangJ-JChenZ-HSerial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trialJ Hematol Oncol2016918627619632
   PubMed Web of Science ®Google Scholar